T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Hackett Group
HCKT
$278M
| $713K | ﹤0.01% |
34,743
-7,588
| -18% | -$159K |
|
|
MRSN
2202
DELISTED
Mersana Therapeutics
MRSN
| $712K | ﹤0.01% |
4,578
-34,658
| -88% | -$6.74M |
|
2203
Empire State Realty Trust
ESRT
$817M
| $709K | ﹤0.01% |
79,670
+37,264
| +88% | +$368K |
|
2204
Mueller Industries
MLI
$15.1B
| $708K | ﹤0.01% |
47,692
-3,536
| -7% | -$47.8K |
|
2205
Chefs' Warehouse
CHEF
$4.53B
| $707K | ﹤0.01% |
21,240
-527
| -2% | -$17.4K |
|
|
WIRE
2206
DELISTED
Encore Wire Corp
WIRE
| $707K | ﹤0.01% |
4,944
-2,563
| -34% | -$332K |
|
2207
1-800-Flowers.com
FLWS
$262M
| $706K | ﹤0.01% |
30,227
-400
| -1% | -$11.6K |
|
2208
Wabash National
WNC
$507M
| $704K | ﹤0.01% |
36,060
-14,320
| -28% | -$249K |
|
2209
Oric Pharmaceuticals
ORIC
$1.42B
| $702K | ﹤0.01% |
+47,769
| New | +$745K |
|
2210
Revolve Group
RVLV
$1.69B
| $702K | ﹤0.01% |
12,534
+5,621
| +81% | +$395K |
|
2211
Astec Industries
ASTE
$994M
| $701K | ﹤0.01% |
10,120
-390
| -4% | -$24.4K |
|
2212
NewMarket
NEU
$8.72B
| $701K | ﹤0.01% |
2,046
-173
| -8% | -$59.7K |
|
2213
BridgeBio Pharma
BBIO
$15.9B
| $700K | ﹤0.01% |
41,986
-2,507
| -6% | -$106K |
|
2214
Teck Resources
TECK
$31.3B
| $700K | ﹤0.01% |
24,279
+468
| +2% | +$12.8K |
|
|
NEUE
2215
DELISTED
NeueHealth
NEUE
| $698K | ﹤0.01% |
2,538
-264,127
| -99% | -$122M |
|
|
JWN
2216
DELISTED
Nordstrom
JWN
| $696K | ﹤0.01% |
30,766
-2,210,526
| -99% | -$58.6M |
|
2217
Brookfield Renewable
BEP
$10.3B
| $694K | ﹤0.01% |
19,378
+10,406
| +116% | +$383K |
|
2218
RadNet
RDNT
$6.08B
| $691K | ﹤0.01% |
22,964
-4,052
| -15% | -$119K |
|
2219
NETSCOUT
NTCT
$2.87B
| $690K | ﹤0.01% |
20,846
-2,577
| -11% | -$78.1K |
|
2220
CVR Energy
CVI
$3.52B
| $685K | ﹤0.01% |
40,750
+1,563
| +4% | +$27.7K |
|
2221
Banner Corp
BANR
$2.5B
| $684K | ﹤0.01% |
11,276
-646
| -5% | -$38.2K |
|
2222
Peapack-Gladstone Financial
PGC
$822M
| $683K | ﹤0.01% |
19,299
-9,459
| -33% | -$324K |
|
|
WGSWW
2223
DELISTED
GeneDx Holdings Warrant
WGSWW
| $683K | ﹤0.01% |
696,994
| – | – |
|
|
EQRXW
2224
DELISTED
EQRx, Inc. Warrant
EQRXW
| $683K | ﹤0.01% |
+656,593
| New | +$1.2M |
|
2225
Coeur Mining
CDE
$19B
| $682K | ﹤0.01% |
135,324
-14,596
| -10% | -$87.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.